Komori
Medikit (7749) · InitiativeRestated

Establishing a Competitive Group Structure

First written in FY2016. 6 of 7 entries say "Restated". Latest entry: FY2026.

7entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20262016: 120162017: 020172018: 120182019: 020192020: 120202021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Group handles operations consistently from product development through production and sales, and has established a system for delivering high-quality products to customers efficiently. At the same time, by maintaining a corporate structure in which the Group’s sales company and its consolidated subsidiary 東郷メディキット㈱, which handles development and manufacturing, are separate companies, the Group clarifies the roles of each company and works to pursue both growth and profitability in a balanced manner.」

    The Group continues the separate roles of its sales and manufacturing companies and its integrated system from development through sales.
  2. FY2025RestatedAnnual report

    「The Group handles operations consistently from product development through production and sales, and has established a system for delivering high-quality products to customers efficiently. At the same time, by maintaining a corporate structure in which the Group’s sales company and its consolidated subsidiary 東郷メディキット㈱, which handles development and manufacturing, are separate companies, the Group clarifies the roles of each company and works to pursue both growth and profitability in a balanced manner.」

    The Group continues the division of roles between sales and manufacturing companies and its integrated system from development through sales.
  3. FY2022RestatedAnnual report

    「The Group handles operations consistently from product development through production and sales, and has established a system for delivering high-quality products to customers efficiently. At the same time, by maintaining a corporate structure in which the Group’s sales company and its consolidated subsidiary 東郷メディキット㈱, which handles development and manufacturing, are separate companies, the Group clarifies the roles of each company and works to pursue both growth and profitability in a balanced manner.」

    The company continues to describe the division of roles between sales and manufacturing companies and the integrated system from development through sales as the foundation of Group operations.
  4. FY2021RestatedAnnual report

    「The Group is confident that cooperation among its group companies will strengthen the entire flow from product development through production, sales and logistics. The sales companies identify customer needs and translate them into sales, while the manufacturing companies develop and manufacture products based on those needs. By clearly defining their respective roles and working together, the Group will achieve the smooth launch of products that address market needs.」

    The company explains that the division of roles between sales and manufacturing companies now extends across development, production, sales and logistics, while continuing its existing policy of cooperation across the Group.
  5. FY2020RestatedAnnual report

    「The Group handles operations consistently from product development through production and sales, and has established a system for delivering high-quality products to customers efficiently. At the same time, by maintaining a corporate structure in which the Group’s sales company and its consolidated subsidiary 東郷メディキット㈱, which handles development and manufacturing, are separate companies, the Group clarifies the roles of each company and works to pursue both growth and profitability in a balanced manner.」

    The Group continues to explain the division of roles between its sales and manufacturing companies and its integrated system covering development, production and sales.
  6. FY2018RestatedAnnual report

    「The Group regards coordination among its group companies as one of the challenges in efficient product development. By clearly defining the respective roles of the sales companies, which explore customer needs, and the manufacturing companies, which pursue early-stage development, and working together, the Group will achieve the smooth launch of products that address market needs. It will also strengthen cooperation among group companies and establish production, inventory-control and sales-management systems that can respond more flexibly to customer needs.」

    The Group continues to emphasize the division of roles between sales and manufacturing companies, smoother product launches, and the establishment of production, inventory-control and sales-management systems.
  7. FY2016First statedAnnual report

    「We are strengthening ties between our R&D staff and sales representatives to jointly identify the needs of university hospitals and other medical institutions. We promptly communicate the research issues identified through this process to our manufacturing companies, work to shorten development times, and promote joint development with physicians and others. We will also strengthen cooperation across the Group and establish production, inventory-control and sales-management systems that can respond more flexibly to customer needs.」

    The company identifies stronger coordination among R&D, sales and manufacturing, joint development, and the establishment of management systems as key measures.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Medikit's next results are scheduled for 2026-11-12. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Establishing a Competitive Group Structure | MEDIKIT CO.,LTD. (7749) | Komori